World's Best Scientists 2026 revealed!
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
134
Citations
90399
World Ranking
2109
National Ranking
23

Rafael Rosell publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Rafael Rosell sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,260 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Rafael Rosell D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Rafael Rosell sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 134 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Rafael Rosell is affiliated with the Autonomous University of Barcelona in Spain. Their research primarily focuses on Medicine, with a concentration in Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Cancer Research.

Key topics in their work include:

  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Cancer therapeutics and mechanisms
  • Lung Cancer Research Studies
  • Peptidase Inhibition and Analysis
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Genomics and Diagnostics

Among their recent publications are:

  • Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial, 2024, The Lancet Respiratory Medicine
  • Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer, 2020, UNC Libraries
  • 285 (PB273): RET overexpression in absence of fusions or mutations associates with sensitivity to RET TKIs in lung cancer, 2024, European Journal of Cancer
  • Cross-Method Comparison for Braf P.V600 Mutation Cfdna Testing in Melanoma: Brafi Study, 2025, SSRN Electronic Journal
  • Cross-Method Comparison for Braf P.V600 Mutation Cfdna Testing in Melanoma: Brafi Study, 2025, SSRN Electronic Journal

Frequent co-authors in their research collaborations include:

  • María González-Cao
  • Miguel Ángel Molina-Vila
  • Ana Drozdowskyj
  • Ruth Román
  • Clara Mayo de las Casas

Key venues where Rafael Rosell has published work include:

  • SSRN Electronic Journal
  • The Lancet Respiratory Medicine
  • UNC Libraries
  • European Journal of Cancer
  • Toxicology Letters

Best Publications

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    Rafael Rosell;Teresa Moran;Cristina Queralt;Rut Porta

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial

    Jean Yves Douillard;Rafael Rosell;Mario De Lena;Francesco Carpagnano

  • A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

    R Rosell;J Gómez-Codina;C Camps;J Maestre

  • Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

    Zhenfeng Zhang;Zhenfeng Zhang;Jae Cheol Lee;Luping Lin;Victor Olivas

  • Detection of Aberrant Promoter Hypermethylation of Tumor Suppressor Genes in Serum DNA from Non-Small Cell Lung Cancer Patients

    Manel Esteller;Montserrat Sanchez-Cespedes;Rafael Rosell;David Sidransky

  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

    Yi-Long Wu;Ying Cheng;Xiangdong Zhou;Ki Hyeong Lee

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

    H. J. N. Andreyev;A. R. Norman;D. Cunningham;J. Oates

  • Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

    Reginald V N Lord;Jan Brabender;David R Gandara;Vicente Alberola

  • Non-small-cell lung cancer

    Cesare Gridelli;Antonio Rossi;David P Carbone;Juliana Guarize

  • Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

    Andrea Ardizzoni;Luca Boni;Marcello Tiseo;Frank V. Fossella

  • A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non–Small-Cell Lung Cancers

    Mariano Monzó;Rafael Rosell;Enriqueta Felip;Julio Astudillo

  • Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

    Manuel Cobo;Dolores Isla;Bartomeu Massuti;Ana Montes

  • Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

    Felipe Cardenal;M. Paz López-Cabrerizo;Antonio Antón;Vicente Alberola

Frequent Co-Authors

Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Mariano Provencio
Mariano Provencio Autonomous University of Madrid
Tony Mok
Tony Mok Chinese University of Hong Kong
Giorgio V. Scagliotti
Giorgio V. Scagliotti University of Turin
Jacek Jassem
Jacek Jassem Gdańsk Medical University
Alfredo Carrato
Alfredo Carrato University of Alcalá
Rolf A. Stahel
Rolf A. Stahel University of Zurich
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
Alice T. Shaw
Alice T. Shaw Harvard University
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in Medicine but want flexible or alternative options, there are several related online degrees and career pathways to explore. Programs like a bachelor of health information management online can prepare you for critical healthcare roles—without the need for traditional, on-campus study.

Another rapidly growing field is medical billing and coding. If you’re curious about the training, you may wonder how much does it cost to become a medical coder. Online programs offer affordable and flexible pathways into this in-demand profession.

For those aiming for advanced clinical roles, nurse practitioner programs are also widely available online. Students often seek the cheapest np school options to keep tuition affordable while boosting their career opportunities.

In nursing, there are many accredited and accessible pathways as well. Prospective registered nurses can research the cheapest online bsn programs to earn their degree from home, saving money and gaining flexibility in the process.

Best Scientists Citing Rafael Rosell

Trending Scientists

Recently Published Articles